Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 16/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Noraristeromycin SCHEMBL19644993 | 1.00 | AHCY (1.00) | AHCYADORA2BADORA3 | |
| Noraristeromycin SCHEMBL8886019 | 1.00 | AHCY (1.00) | AHCYADORA2BADORA3 | |
| Noraristeromycin SCHEMBL1231088 | 1.00 | AHCY (1.00) | AHCYADORA2BADORA3 | |
| Noraristeromycin SCHEMBL26381984 | 1.00 | AHCY (1.00) | AHCYADORA2BADORA3 | |
| Noraristeromycin SCHEMBL17117186 | 1.00 | AHCY (1.00) | AHCYADORA2BADORA3 | |
| Noraristeromycin SCHEMBL29378522 | 1.00 | AHCY (1.00) | AHCYADORA2BADORA3 | |
| SCHEMBL12149495 | 0.93 | AHCY (0.86) | AHCYADORA2BADORA3 | |
| SCHEMBL14635767 | 0.87 | AHCY (1.00) | AHCYADORA2B | |
| SCHEMBL17302275 | 0.86 | AHCY (1.00) | AHCYADORA2B | |
| SCHEMBL26382107 | 0.86 | AHCY (1.00) | AHCYADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266918-A1 | Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides | ZHONG MINGHONG (US) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266918-A1 | Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides | TYMP, ENPP3, PNP | AHCY 3087/4885ADORA2B 147/4885ADORA3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.